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 Purpose of review  
Recent placebo literature provides  the scientific basis for the different psychological factors that 
influence the outcome of a medical treatment. The aim of the present review is to summarize the 
recent findings of placebo research offering useful tools for everyday medical routine.  
Recent findings 
Treatment efficacy is influenced by the patient’s expectations of therapeutic benefit. Indeed, 
positive or negative expectations may lead to symptom improvement or worsening, respectively. 
Therefore, in clinical practice, patients’ expectations and beliefs need to be considered and 
controlled appropriately. In addition, previous experience influences the healing process, as shown 
by classical conditioning studies. This knowledge can be used to increase the effect of 
pharmacological or procedural treatments, to reduce drug intake, and to minimize psychological 
adverse events. Overall, a significant enhancement of the therapeutic outcome can be obtained by 
potentiating empathic communication and establishing a cooperative patient-provider relationship.  
Summary 
Placebo research provides solid scientific ground for all those psychological aspects that 
characterize every medical treatment. It also gives us information on the functioning of the human 
brain, with the possibility to exploit some of these mechanisms in routine medical practice. 
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Key points 
 Placebo research provides scientific ground for the use of practical tools to improve daily 
medical routine. 
 Patient’s beliefs and expectations about the outcome represent crucial factors in every 
medical treatment, influencing therapy efficacy. 
 The use of cooperative and empathic approaches should be encouraged, to increase patients’ 
expectations. 
 Patients’ previous experiences and learning through classical conditioning mechanisms 
could be exploited for optimization of drug administration.  
 The open/hidden protocol of drug administration allows enhancement of patient’s awareness 
of the therapy and minimization of adverse effects of therapy interruption. 
 
Introduction  
In the course of history, medical practice has considerably changed. The ancient and 
primitive medicine of shamans and priests was psychological in nature, and centered on words and 
rituals. The outcome of those psychological treatments was in many cases remarkable and aimed to 
treat the person. Modern medicine, also called “evidence-based”, consists in the administration of 
specific drugs and treatments, which first have to be tested in a randomized double blind placebo 
controlled trial. The healing effect of these chemical treatments is surely important, nonetheless it is 
aimed at treating the disease rather than the person. In spite of the clear advantage of modern 
medicine, we are now witnessing increasing interest and awareness of the importance of the 
psychological factors that surround every medical act. This knowledge comes from different fields. 
On the one hand palliative medicine is promoting a healing process which aims to take care of the 
person rather than to cure the disease: it emphasizes the care of the personal, physical and social 
needs of the patient, the quality of life and the relationship and communication between doctor and 
patient. On the other hand, research about the placebo effect has demonstrated the crucial role of the 
psychosocial context, leading to a comprehensive model of medicine that includes both chemical 
and psychological processes. Indeed, any therapeutic treatment, be it pharmacological or 
procedural, can be described as the result of two different processes, both contributing to the 
therapeutic benefit: the specific chemical process, i.e. the action of the pharmacological agent (e.g. 
morphine), and the ritual process, i.e. the psychosocial context surrounding the treatment, including 
the act of its administration (e.g. the color of the morphine pill, the words used to describe the 
features of the drug, and such like). In a placebo treatment the active drug is replaced with an inert 
substance (placebo) and only the ritual process is present. Accordingly, the placebo effect and its 
opposite nocebo effect, can be defined as the neurobiological modifications that occur in the 
patient’s brain after the simulation of a therapy [1**]. Remarkable placebo effects have been shown 
in several conditions, such as pain [2*-4], itch [5], Parkinson’s disease [6-9], depression [10-11], 
anxiety [12-13], immune functions [14-17], motor performance [18-20], asthma [21**].  
Modern neuroscience have focused on two main aspects related to the placebo effect: first, the 
identification of the placebo underpinnings, such as the systems and the brain regions responsible 
for the placebo phenomenon, and second, the implications of placebo research for clinical practice. 
For example,  the opioid system [22-27**] and the anti-opioid cholecystokinin (CCK) system [28-
29] have been found to be involved. In addition, recent work has also shown that the 
endocannabinoid system mediates the non-opioid component of placebo analgesia [30**] and 
dopaminergic and serotoninergic systems have been documented in Parkinson’s disease and social 
anxiety, respectively [6-7-9-13]. Neuroimaging studies have also demonstrated that the placebo 
effect occurs along with the activation of a complex neural network, with prefrontal areas playing a 
crucial role [25,31-36*,37*].  
Rather than focusing on these neurobiological, neuropharmacological and neuroanatomical 
advances of placebo research, which are described in detail in other reviews [38-41], in the present 
article we want to discuss some practical implications which have emerged in the course of the past 
years. We believe that these implications have the potential to positively affect the practice of those 
health professionals who work in the palliative care setting, who have to use the appropriate words, 
and who have to adopt the adequate attitudes and behaviors in their everyday medical practice.   
 
Work with expectations  
The expectation of an outcome represents a crucial factor in every medical treatment. In fact, 
a therapeutic procedure produces an effect partly because of the patient’s expectations. These can 
be fostered by an internal locus of control (e.g. “I believe in myself and with the help of the drug I 
can cope with the disease) or by an external locus of control (e.g. “The doctor told me that the drug 
is so powerful that I will get better soon) [42]. Indeed, according to the cognitive theory of placebo, 
cognitive processes such as expectancy, anticipation, motivation, desire, belief, and optimism [43] 
are at play in the healing process. These are conscious processes activated by several factors, such 
as verbal instructions, patient-doctor interaction, emotional arousal of the patient. Different studies 
have investigated the role of these factors in both the laboratory and the clinical contexts. Recently, 
in the laboratory setting VanLaarthoven et al. [5] have manipulated expectations through verbal 
suggestions in a new experimental model of itch. Different somatosensory stimuli were delivered 
along with high (nocebo) or low (control) expectations of itch. As expected, following the 
suggestions of itch increase the subjects experienced significantly higher levels of itch compared 
with controls. The power of expectation through verbal suggestions has been documented also in 
clinical conditions. In a double-blind study, patients with asthma were randomly assigned to receive 
an active treatment with an albuterol inhaler, a placebo inhaler, sham acupuncture or no intervention 
[21**]. Even if albuterol administration resulted in a 20% increase in the forced expiratory volume 
(FEV1), the patients reported no subjective differences between albuterol and placebo treatments. In 
terms of subjective outcome therefore, the placebo effect proved equivalent to the drug effect, 
confirming the importance of the patient’s expectation about therapy effectiveness. In another study 
with Parkinson’s disease patients, participants were told that they had a specific probability (25%, 
50%, 75% or 100%) of receiving dopamine but they actually always received a placebo [9]. 
Significant dopamine release in the nigrostriatal and mesoaccumbens pathways occurred when the 
declared probability of receiving active medication was 75%, suggesting a close relationship 
between the improvement belief and the resultant clinical benefit. In a different study, it was 
demonstrated that the open-label administration of a placebo in irritable bowel syndrome (IBS) 
patients produces an improvement in IBS symptoms when patients know that “the placebo, at least 
in some circumstances, works as a real drug through the release of endogenous-opioids” [44]. 
Therefore, the knowledge and the understanding of a treatment boost positive expectations which, 
in turn, lead to symptom amelioration.  
 
Use empathy and cooperation 
Besides the importance of knowing and understanding the effect of a treatment, a second 
important aspect is represented by the patient’s needs. There are both cognitive and affective needs,  
the later being aimed at creating an empathic doctor-patient relationship [45]. Kelley et al. [46]  
investigated the affective needs in an experimental design with placebo acupuncture. IBS patients 
were divided into three groups. Two groups were treated with placebo acupuncture with either a 
warm empathic interaction, or a neutral interaction: the only difference between the two conditions 
was the quality of interpersonal interaction between the practitioner and the patient (warm and 
empathic or neutral and minimal). A third group (waiting list group) was periodically monitored but 
no treatment was delivered. A single outcome measure was constructed by combining 4 different 
IBS symptom scales. The empathic interaction produced an improvement compared with the neutral 
or waiting list interactions. This study highlights the importance of the clinical interaction during 
the healing process but does not differentiate between the emotional and the cognitive needs. The 
difference between these two aspects has been documented in a recent work [47], in which either 
empathic or cold communication was combined with positive or uncertain expectations about the 
effect of a painkiller on menstrual pain, in a 2 x 2 randomized control trial. Only warm and 
empathic communication with positive expectation led to a relevant decrease in anxiety state. Even 
if no measures of pain rating were reported, the key role of communication style is nonetheless 
documented, suggesting important implications for medical practice. 
In the last decade the relationship between doctor and patient has considerably evolved. 
From a directive approach, in which the doctor prescribed a specific cure to the patient without 
discussion, a better refinement of the informed consent has increased the patient involvement in the 
therapeutic process, leading to a more cooperative relationship, embracing both cognitive and 
emotional needs. Rose et al. [48*] studied the effect of this cooperative relationship by testing the 
effect of the treatment choice. Participants underwent the cold pressor test for pain tolerance 
following the application of a novel painkiller (actually a placebo). They were split in three groups: 
a “choice” group was permitted to choose the analgesic treatment to be used during the pain task, a 
“no-choice” group received a random treatment and a control group was administered a treatment 
without eliciting expectations or giving a choice. Pain ratings were obtained during the test at 
different times, and after the test by means of a questionnaire. The choice group experienced less 
pain during and after the test compared with the no-choice and control groups, and the authors 
suggested a possible involvement of anxiety mechanisms. These results are useful especially in light 
of the recent emphasis on “patient-oriented” medicine [49]. Indeed the authors suggest that one 
positive consequence of the enhanced involvement of the patient in a therapy is a greater placebo 
response. On the whole, the increase of patients’expectations and the use of a cooperative and 
empathic approach clearly enhances medical treatments.  
 
Use previous experiences and learning  
The placebo literature has taught us that, in some circumstances, the healing process can be 
due to classical conditioning. For example, a painkiller is a significant event (unconditioned 
stimulus, US) that induces per se a natural response such as analgesia (unconditioned response, 
UR), whereas the physical features of the painkiller (e.g. shape, color, taste) or contextual cues that 
accompany its administration (e.g. hospital environment, white coats, or syringes) are neutral 
stimuli (conditioned stimuli, CS) that are not related to a specific innate behaviour. However, after 
repeated associations between the CS and the US (acquisition phase), the CS alone (evocation 
phase) can evoke the therapeutic benefit (conditioned response, CR). Following this schema, the 
placebo effect can be considered a learned CR that takes place after the repeated pairing between 
the CS and the US [50]. As recently shown, the higher the number of US-CS pairings, the stronger 
the placebo response [3]. The authors delivered tactile and painful stimuli on the dorsum of the foot, 
and exposed the volunteers to 1 or 4 conditioning sessions in which decreased (placebo) or 
increased (nocebo) perceived intensities (US) were induced and paired with green or red lights 
(CS), respectively. After 4 conditioning trials the subjects experienced more robust placebo and 
nocebo responses that lasted for the entire experiment. This study suggests that prior exposure to 
effective treatments may be clinically important, inducing long-lasting placebo responses. At the 
same time, avoiding  negative experiences is crucial, in order to prevent the occurrence of nocebo 
effects. 
In a clinical setting, Ader et al. [51] used a conditioning procedure to reduce the drug 
regimen while at the same time maintaining the symptoms improvement. Following an acquisition 
phase during which a corticosteroid therapy was given, patients with psoriasis were treated for eight 
weeks in different ways: a first group was administered a full medication for the entire experiment 
(standard therapy group without conditioning), a second received the full medication for 25-50% of 
the time and a placebo medication for the remaining time (conditioning group with partial 
reinforcement), a third group was treated with 25-50% of the full dose for the entire experiment 
(dose control group). A similar improvement was observed in the standard therapy and conditioning 
groups by using the Psoriasis Severity Scale index, whereas the dose control group showed severe 
worsening. This study demonstrates that the intermittent reinforcement, consisting in the combined 
administration of real drugs and placebos, is capable of producing beneficial effects, with the 
further advantage of reducing possible side effects often associated with a long lasting 
pharmacological treatment [52].  
 
Enhance the knowledge about the therapy and avoid symptom worsening 
 In current medical practice, the doctor usually notifies the patient about the timing and 
effects of a treatment: this modality can be defined “open” or “expected”, because the patient is 
aware of the treatment administration and expects the therapeutic benefit. Conversely, when the 
patient receives the treatment without information about its administration (e.g. when the therapy is 
delivered by a computer-controlled infusion pump) the condition can be defined “hidden” or 
“unexpected”, because no expectations about the therapeutic outcome are elicited. Of course, in 
both the open and hidden conditions the same analgesic is administered, so that the only difference 
between the two conditions is represented by the patient’s expectations of clinical improvement 
[53**]. In a recent fMRI study [54**], it was shown that a hidden administration of a painkiller 
induced pain decrease, associated with decreased activity in several pain matrix regions, such as the 
primary somatosensory cortex, the insula, the anterior cingulate cortex and the thalamus. However, 
the effect doubled after an open administration, with increased activity in the pregenual anterior 
cingulate cortex and the dorsolateral prefrontal cortex. Therefore, in this study the psychological 
component, represented by the expectations of being treated, enhanced the pharmacological effect 
of the painkiller. 
In another study, Bjorkedal et al. [55] used caffeine as an active placebo, i.e.  a drug without effects 
on the symptom under investigation but mimicking the side effect of the active treatment. Zero or 4 
mg/kg of caffeine were administered along with suggestions of analgesia (placebo and active 
placebo groups, respectively) or with no information (control or caffeine group, respectively) about 
the administration of a painkiller. The results showed that 4 mg/kg of caffeine reduced pain, and 
that the expectation of painkiller administration produced longer analgesia compared with the no-
information group. As suggested by the authors, the drug might have provided an interoceptive cue 
interacting with the verbal information. Overall, the open-hidden design highlights the key role of 
medical rituals and expectations.   
Whereas the open administration of a treatment boosts the pharmacological effect of the drug, the 
open interruption of a therapy may lead to opposite effects, for the ritual of interruption may induce 
negative expectations of worsening. Interestingly, the relapse of symptoms in both pain and anxiety 
is faster with an open compared with a hidden interruption [53**]. Psychological adverse reactions 
(nocebo effects) can also be produced in clinical practice by the informed consent, in which the 
possible occurrence of side effects is usually described in some detail [56]. It is therefore necessary 
to find a compromise between the opposing needs of information disclosure and nocebo effects 
minimization.  
 
Conclusions 
The placebo effect is an interesting topic for neuroscience because it represents a good example of 
the top-down influence of cognitive factors on behavior. Health professionals often know that 
emphatic communication and cooperation, attention to the context, patients’ expectation and 
previous experiences, are important factors to be considered for a positive outcome. This common 
knowledge is now given scientifically sound ground by the findings of placebo research,  which can 
be incorporated into a sort of “vade mecum” for better clinical practice. 
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